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1  | BACKGROUND
The capacity of an individual to mount an effective immune response 
to infection is entirely dependent upon their inherited complement 
of human leucocyte antigens (HLA) which present pathogenic 
peptides to T and B lymphocytes. The repertoire of the viral pep-
tides bound by each individual is dependent upon sequence variation 
within the antigen recognition site of their HLA molecules. This has 
recently been underlined in the twin study of Williams et al. (2020). 
The HLA type of the patient is likely to be a significant influencing 
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Abstract
We analysed data from 80 patients who tested positive for SARS-CoV-2 RNA who 
had previously been HLA typed to support transplantation. Data were combined 
from two adjacent centres in Manchester and Leeds to achieve a sufficient number 
for early analysis. HLA frequencies observed were compared against two control 
populations: first, against published frequencies in a UK deceased donor popula-
tion (n = 10,000) representing the target population of the virus, and second, using 
a cohort of individuals from the combined transplant waiting lists of both centres 
(n = 308), representing a comparator group of unaffected individuals of the same 
demographic. We report a significant HLA association with HLA- DQB1*06 (53% vs. 
36%; p < .012; OR 1.96; 95% CI 1.94–3.22) and infection. A bias towards an increased 
representation of HLA-A*26, HLA-DRB1*15, HLA-DRB1*10 and DRB1*11 was also 
noted but these were either only significant using the UK donor controls, or did not 
remain significant after correction for multiple tests. Likewise, HLA-A*02, HLA-B*44 
and HLA-C*05 may exert a protective effect, but these associations did not remain 
significant after correction for multiple tests. This is relevant information for the clini-
cal management of patients in the setting of the current SARS-CoV-2 pandemic and 
potentially in risk-assessing staff interactions with infected patients.
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factor in an infected individual's ability to produce an effective im-
mune response (Ishibashi et al., 2009). A number of in silico studies 
have defined the potential for immune responsiveness based on dif-
ferential viral peptide binding to HLA alleles (Fast, Altman, & Chen, 
2020; Nguyen et al., 2020). These are useful in vaccine design but do 
not represent the situation in natural infection where the full HLA 
type of the individual, comprising up to twelve alleles across six loci, 
informs the capacity for immune response. This study investigated 
HLA profiles of patients admitted with PCR-confirmed SARS-CoV-2 
infection to identify any potential HLA bias which might indicate an 
impaired capacity to mount an effective immune response to the in-
fection. The information is of value towards risk stratification and 
clinical management of patients and potentially in risk-assessing 
staff interactions with infected patients.
2  | METHODOLOGY
The aim of this study was to analyse the HLA types of individuals 
receiving hospital care for COVID-19 symptoms, where the HLA 
type was already known. The inclusion criteria for this study were 
(a) that the patient must have been previously HLA typed at least 
at HLA-A, B, C, DRB1 and DQB1 and (b) must have a positive test 
for the presence of SARS-CoV-2 RNA. A total of 80 patients were 
included in the study, 41 from Manchester and 39 from the Leeds 
transplant centre. Data were combined from both units to achieve 
a sufficient number for early analysis. All patients included in the 
study had previously been HLA typed to support transplantation 
and required hospital treatment for COVID-19 disease, indicating 
that their symptoms were severe, requiring clinical support or inter-
vention. Patients included in the study were either kidney transplant 
patients (n = 33), individuals on the solid organ transplant waiting 
lists (n = 40), or patients who had received haematopoietic stem cell 
transplantation (n = 7). For the Leeds patients, the male:female ratio 
was 32:8, and the median age was 60.6 years (range 27–87 years). 
For the Manchester patients, the male:female ratio was 20:20, and 
the median age was 58.9 years (range 3–80 years).
HLA typing had been performed using either of two methods: 
(a) LABType®SSO HLA Class I (HLA-A, B and C) and HLA Class II 
(DRB1/3/4/5 and HLA-DQ) loci (OneLambda Inc), or (b) next-gen-
eration sequencing (HOLOTYPE HLA™; Omixon or TruSight HLA, 
Illumina). All tests were performed according to manufacturers’ in-
structions. HLA frequencies were analysed at first field resolution, 
and where second field typing data were available, types were con-
verted into a serological equivalent specificity for analysis.
3  | CONTROL POPUL ATIONS
We have performed analyses against two control populations Group 
A: a UK (n = 10,000) deceased donor pool13 (https://nhsbtdbe.blob.
core.windows.net/umbrarco-assets-corp/2925/antigen.pdf)and 
Group B: a local (n = 308) wait-listed renal patient cohort comprising 
the active wait list from Leeds (n = 150) and a randomly selected co-
hort (n = 158) from the Manchester centre. The rationale behind the 
use of two separate control groups was an acknowledgement that 
problems exist in respect of both. Control Group A is representative 
of the UK population and the infection target of the virus, but it lacks 
proportionate representation of Black, Asian and Minority Ethnic 
(BAME) groups. Comparisons made with transplant patient groups 
may be confounded by this variance. The advantage of using the 
control Group A in the context of this study is, however, that it rep-
resents a population assembled prior to the SARS-CoV-2 pandemic. 
Conversely, the n = 308 cohort (Group B) is derived by combining 
unselected individuals on the renal transplant waiting list from each 
centre, but the SARS-CoV-2 infection/exposure history of the group 
is uncertain and incorrect inferences may then be drawn from its 
use. Alternative control groups were considered but precluded on 
the basis of the problems in their confident construction at this time.
3.1 | Statistical analysis
Statistical analysis was performed using MedCalc v19.3 (MedCalc 
Software) to compare frequencies of allele group carriage be-
tween the patient and control populations using Fisher's exact test. 
Odds ratios were calculated at 95% confidence intervals (CI) using 
MedCalc software. Each allele group was compared independently, 
and p ≤ .05 was considered to be significant. Bonferroni correction 
was applied to accommodate multiple testing within each locus 
tested (Gaetano, 2018). The allelic frequencies were assessed in all 
populations.
Allele group carriage is defined as the number of individuals car-
rying the respective allele group. Allelic frequencies are defined as 
the number of occurrences of the respective allele group divided by 
the total number of allele groups in the cohort. An allele group was 
considered to raise the risk of viral susceptibility when the OR was 
above 1 and considered protective against viral susceptibility when 
OR was below 1.
4  | RESULTS
Allele group carriage frequencies for all specificities where as-
sociations which were significant, or approaching significance are 
included in Table 1. Seventeen of the top twenty most frequent 
HLA haplotypes in the UK population (allelefrequencies.net) were 
represented in this cohort revealing a broad susceptibility to infec-
tion. When comparing our patients with control Group A, there 
were more significant associations observed than when compared 
against control Group B. The strongest associations observed in risk 
of viral susceptibility observed were with HLA Class II specificities. 
After Bonferroni correction, HLA-DQB1*06 remains a significantly 
increased risk when compared with Group B controls, but not Group 
A controls (Group A: 52.5% vs. 41.0%; p = .0402, pc = not significant; 
OR = 1.59 CI 1.02–2.47; p = .0390, pc = not significant; Group B: 
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52.5% vs. 36.0%; p = .0100, pc = .0523; OR = 1.96 CI 1.19– 3.22; 
p = .0078; pc = .0468.) Additionally, there is a significant bias in this 
group of patients which did not retain significance after the ap-
plication of Bonferroni correction with higher-than-expected fre-
quencies of HLA-DRB1*15 (Group A: 40.0% vs. 28.0%, p = .0238; 
OR = 1.71 CI 1.09–2.68, p = .0187; Group B: 40.0% vs. 25.3%, 
p = .0121; OR = 1.97 (1.17–3.29), p = .0102) and DRB1*11 (Group 
A: 22.5% vs. 13.0%, p = .0185; OR = 1.94 CI 1.15–3.29, p = .0137; 
Group B: 22.5% vs. 18.8%, p = not significant) in our patient group. 
The antigens comprising the HLA-DQ1 group (HLA-DQB1*05 and 
DQB1*06), which are in tight linkage disequilibrium with HLA-
DRB1*15 and HLA-DRB1*10, were collectively of raised risk (Group 
A: 72.5% vs. 58.0%; p = .0087, pc = .0523; OR = 1.91 CI 1.17–3.12; 
Group B: 72.5% vs. 60.1%; p = .0513, pc = not significant; OR = 1.96 
CI 1.19–3.22, p = .0421, pc = not significant). When the broad spe-
cificities were considered independently, HLA-DQB1*05 was not 
significant in its correlation with viral infection, suggesting that the 
primary association lies with DQB1*06, rather than DQ1. With such 
a small cohort, it is not possible to ascertain whether these observa-
tions are due to linkage disequilibrium between HLA-DR and DQ, or 
whether this is an independent observation. For HLA Class I, HLA-
A*26 was also significantly increased in the patients compared with 
Group A controls (11.3% vs. 4.0%; p = .0049, pc = .0198; OR = 3.04 
CI 1.50–6.13, 0.0019, pc = .0076). These data need to be interpreted 
cautiously as the associations reaching significance against Group A 
controls are based on comparison with a UK population and HLA-
DRB1*10 and HLA-A*26 are known to be represented at higher 
frequency in the BAME populations. Neither of these associations 
remained significant when compared with the local population of 
Group B controls.
A number of HLA alleles appeared to exert a protective effect 
when compared with the Group A controls and were identified at 
lower-than-expected frequencies in our patient population. For ex-
ample, HLA-A*02 (36.3% vs. 50.0%, p = .0179, pc = .0536; OR = 0.57 
CI 0.36–0.90, p = .0156, pc = .0468), B*44 (18% vs. 32%, p = .0052, 
pc = .0105; OR = 0.45 CI 0.25–0.80, p = .0069, pc = .0138)C*05 (9% 
vs. 21%, p = .0054, pc = .0215; OR = 0.36 CI 0.17–0.78, p = .0101, 
pc = .0404), DRB1*04 (22.5% vs. 35.0%, p = .0185, pc = not signif-
icant; OR = 0.54, CI 0.32–0.91, p = .0214, pc = not significant) and 
DRB1*07 (16.3% vs. 26.0%; p = .0539, pc = not significant; OR = 0.55, 
CI 0.30–1.00; p = .0507, pc = not significant). It is of interest that 
HLA-A*02, HLA-B*44 and HLA-C*05 are frequently inherited to-
gether with either DRB1*04 or HLA-DRB1*07 in English population 
(Allele Frequency Net Database allelefrequencies.net) which may 
reinforce the possibility that a protective effect, or a superior im-
mune response to SARS-CoV-2 infection is exerted by these ances-
tral haplotypes.
5  | DISCUSSION
Effective immune clearance of any virus can only be achieved when 
an individual's HLA antigens collectively succeed in presenting 
pathogen-derived peptide efficiently, enabling the generation of 
sufficient antibody to eliminate it. Without this, a situation arises in 
which the reproduction of virus within the host results in ongoing 
invasion, overwhelming the capacity of the affected individual to ef-
fectively clear the infection. In SARS-CoV-2 infection, a high-affinity 
neutralizing antibody response would act in synergy with the pro-
duction within the lung of antiviral cytokines and promotion of the 
TA B L E  1   HLA frequencies in 80 patients with COVID-19 previously HLA typed to support transplantation
HLA
Allele
Group
COVID-19 population
Allele group carriage 
frequency (%; n = 80)
Control Group A
Allele group carriage 
frequency (%; n = 10,000)
Control 
Group A
p
Control 
Group A
pc
Control Group B
Allele group carriage 
frequency (%) (n = 308)
Control 
Group B
p
Control 
Group B
pc
HLA-A*02 36.3 50.0 .0179 .0536 46.4 — —
HLA-A*26 11.3 4.0 .0049 .0198 7.5 — —
HLA-B*44 17.5 32.0 .0052 .0105 19.8 — —
HLA-C*05 8.8 21.0 .0054 .0215 15.9 — —
HLA-C*12 12.5 6.0 .0286 — 11.7 — —
DRB1*15 40.0 28.0 .0238 — 25.3 .0121 —
DRB1*04 22.5 35.0 .0185 — 33.4 — —
DRB1*11 22.5 13.0 .0185 — 18.8 — —
DRB1*07 16.3 26.0 .0539 — 20.8 — —
DRB1*10 6.3 1.0 .0014 .0144 4.5 — —
DQB1*05 35.0 27.0 — — 30.5 — —
DQB1*06 52.5 41.0 .0402 — 36.0 .0010 .0523
Note: The control frequencies are derived from Group A: (n = 10,000) deceased solid organ donors between November 1994 and December 2009 
(https://nhsbt dbe.blob.core.windo ws.net/umbra co-asset s-corp/2925/antig en.pdf) and Group B: a local (n = 308) wait-listed renal patient cohort 
comprising the active wait list from Leeds (n = 150) and a randomly selected cohort (n = 158) from the Manchester centre. Only associations which 
demonstrated significance, or approached significance when compared with either control population are listed. Significance (Fisher's exact) is shown 
before (p) and after (pc) Bonferroni correction. Results which are not significant are represented by (−) in the table.
     |  327POULTON eT aL.
CD8 T-cell response (DiPiazza, Richards, Knowlden, Nayak, & Sant, 
2016).
Individuals infected with SARS-CoV-19 have a variety of clini-
cal manifestations of the disease described as COVID-19 (Huang 
et al., 2020). While almost all patients develop COVID pneumonia, 
approximately 29% cases progress to acute respiratory distress syn-
drome which occurs 10–12 days after the onset of symptoms (Huang 
et al., 2020). Furthermore, individuals who develop respiratory dis-
tress have often been responding well during the first phase of the 
disease, but their symptoms return aggressively, requiring clinical 
support within a hospital environment. This phenomenon is sugges-
tive of an immunological hiatus, in which these individuals have been 
unable to effectively mature their immune response to generate the 
production of potent neutralizing antibody.
In this series of individuals requiring admission following in-
fection with SARS-CoV-2, the possibility presents that possession 
of the HLA Class I type HLA-A*26 or the HLA Class II types HLA-
DQB1*06, HLA-DRB1*15 or HLA-DRB1*10 results in an impaired 
ability to present the viral peptides necessary to form a protective 
T-cell repertoire. An alternative explanation may be that the HLA 
molecule itself is implicated as an attachment factor for the spike 
protein as documented by Chan et al. (2009) in coronavirus HKU1 
infection, where evidence suggests that HLA-C molecules actually 
facilitate the entry of the virus into the cell.
In this regard, HLA-A*26 has previously been identified as 
a predisposing type to infection with visceral leishmaniasis (ka-
la-azar; Singh, Agrawal, & Rastogi, 1997) and has been associated 
with the development of Epstein–Barr virus-driven post-transplant 
lymphoproliferative disorder in solid organ transplantation (Reshef 
et al., 2011). The occurrence of other specificities potentially within 
the HLA-A*26 superset is also noteworthy and is the subject of fur-
ther work in our laboratories. We also note the prediction, based 
on an in silico analysis, for poor ability of the closely related antigen 
HLA-A*25 to present a repertoire of SARS-CoV-2 epitopes in the 
current paper from Nguyen et al. (2020). This paucity would be ex-
pected to impact on the quality of the linked immune response to 
the virus. Utilizing the Immune Epitope Database Analysis resource, 
TepiTool (TepiTool IEDB Analysis Resource), we therefore examined 
the top potential epitopes (Fast et al., 2020) for key SARS-Cov-2 
proteins in regard to their binding affinity to HLA-A*26:01. Based 
on IC50 < 500 nm, only one epitope (FTISVTTE) was identified that 
would be predicted to support a T-cell-based immune response. This 
link between a real-world observation and an in silico predication 
provides validation of both findings. In this study, the individuals 
who were positive for HLA-A*26 were not also positive for HLA-
DRB1*10, although these have been documented to be inherited on 
the same haplotype (allelefrequencies.net).
A study of SARS-CoV-2-positive individuals in a UK Biobank 
population has also identified DRB1*15:01 (OR = 1.33, CI 1.01–1.74) 
and DQB1*06:02 (OR = 1.32, CI 1.01–1.74) to be associated with an 
increased likelihood of testing positive for the virus (Kachuri et al., 
2020). This is an in silico study in which HLA types have been im-
puted, but these observations add support to our own observation 
in regard to HLA-DR15 and DQ6 in this early study of individuals 
with known HLA types. The upregulation of HLA-DR expression 
in lung tissue of patients affected with COVID pneumonia (Wang 
et al., 2020) suggests that this process is instrumental in the im-
munological control of the disease process and therefore must be 
considered to be biologically relevant. HLA-DR10 and DR11(5) have 
previously been implicated in patients with impaired response to cy-
tomegalovirus infection (Ishibashi et al., 2009), while HLA-DR11(5) 
has also been documented to be associated with severe response 
to infection with MERS-Cov (Hajeer, Balkhy, Johani, Yousef, & 
Arabi, 2016). HLA-DR10 has also been proposed to be the vector 
mechanism for viral entry of Epstein–Barr virus into B cells, rein-
forcing the concept that the molecule itself may be a mechanism for 
driving viral infection Li and Cohen (2019). A primary inefficiency of 
the alleles HLA-DQB1*05 and *06 cannot be discounted in this very 
early UK study, due to linkage disequilibrium.
This study has been deliberately independent of ethnicity as 
the UK population in this region of England is genetically heteroge-
neous with multiple populations of different heritages co-existing. 
It could be argued that the use of the UK deceased donors as a 
control population in this study has simply highlighted more fre-
quent occurrence of antigens common to BAME communities in 
our COVID-19 population requiring hospital support for their dis-
ease. Conversely, it may be legitimately argued that the BAME link 
with susceptibility is explained through possession of these anti-
gens. While either point remains valid, other specificities common 
to BAME groups such as HLA-A*34 and DRB1*16 were not impli-
cated as having heightened susceptibility to severe infection in this 
study. HLA-DRB1*10 and A*26 are common within all European 
subregions (Sanchez-Mazas et al., 2017) and offer an independent 
mechanistic explanation for severity of clinical disease in COVID-
19 patients which is independent of skin colour or other immu-
nogenetic variation due to heritage. If a wider study were to be 
conducted in which all individuals positive for SARS-CoV-2 RNA 
could be included, encompassing all ranges of clinical severity from 
mild symptoms to severe infection, it could be predicted that the 
increased frequency of HLA-DRB1*10 and A*26 in individuals with 
the most clinically detrimental symptoms could take on greater sig-
nificance. The identification of these alleles as factors informing 
disease susceptibility underlines the importance of further con-
sideration of HLA and other immunogenetic influences in ongoing 
efforts to address the SARS-Cov-2 pandemic.
These are obviously tentative findings based on a limited number 
of cases in two centres. An unbiased surveillance of the transplant 
population to include those with mild symptoms or no symptoms 
would help to clarify this observation. We are now seeking to accrue 
additional data in substantiation of the association and to extend the 
scope of our study to in order to establish its basis.
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